Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;8(1):e000494.
doi: 10.1136/lupus-2021-000494.

Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial

Rachel L Randell  1 , Lindsay Singler  2 , Anthony Cunningham  2 , Laura E Schanberg  1   2 , Michael Cohen-Wolkowiez  1   2 , Christoph P Hornik  1   2 , Stephen J Balevic  3   2 ; with the CARRA Registry investigators
Collaborators, Affiliations

Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial

Rachel L Randell et al. Lupus Sci Med. 2021 May.

Abstract

Introduction: Direct-to-family clinical trials efficiently provide data while reducing the participation burden for children and their families. Although these trials can offer significant advantages over traditional clinical trials, the process of designing and implementing direct-to-family studies is poorly defined, especially in children with rheumatic disease. This paper provides lessons learnt from the design and implementation of a self-controlled, direct-to-family pilot trial aimed to evaluate the effects of a medication management device on adherence to hydroxychloroquine in paediatric SLE.

Methods: Several design features accommodate a direct-to-family approach. Participants meeting eligibility criteria from across the USA were identified a priori through a disease registry, and all outcome data are collected remotely. The primary outcome (medication adherence) is evaluated using electronic medication event-monitoring, plasma drug levels, patient questionnaires and pill counts. Secondary and exploratory endpoints include (1) lupus disease activity measured by a remote SLE Disease Activity Index examination and the Systemic Lupus Activity Questionnaire; and (2) hydroxychloroquine pharmacokinetics and pharmacodynamics. Recruitment of the initial target of 20 participants was achieved within 10 days. Due to initial recruitment success, enrolment was increased to 26 participants. Additional participants who were interested were placed on a waiting list in case of dropouts during the study.

Discussion and dissemination: Direct-to-family trials offer several advantages but present unique challenges. Lessons learnt from the protocol development, design, and implementation of this trial will inform future direct-to-family trials for children and adults with rheumatic diseases. Additionally, the data collected remotely in this trial will provide critical information regarding the accuracy of teleresearch in lupus, the impact of adherence to hydroxychloroquine on disease activity and a pharmacokinetic analysis to inform paediatric-specific dosing of hydroxychloroquine.

Trial registration number: ClinicalTrials.gov Registry (NCT04358302).

Keywords: antirheumatic agents; autoimmune diseases; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RR’s spouse has current or prior employment and/or stock ownership in Merck & Co, and Biogen. LES has received consulting fees, speaking fees, and/or honoraria from UCB, Sanofi, Bristol Myers Squibb and Sobi (less than $10 000 each), and research support from CARRA. LES serves on the Data and Safety Monitoring Board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. LES is a former board chair and currently sits on the Registry and Research Oversight Committee for CARRA. CPH receives salary support for research from sponsors for drug development in adults and children (https://dcri.org/about-us/conflict-of-interest/). SB consults for UCB.

Figures

Figure 1
Figure 1
Participant recruitment and enrolment. CARRA, Childhood Arthritis and Rheumatology Research Alliance.
See this image and copyright information in PMC

References

    1. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun 2018;11:156–64. 10.1016/j.conctc.2018.08.001 - DOI - PMC - PubMed
    1. Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J Clin Pharmacol 2015;79:357–69. 10.1111/bcp.12305 - DOI - PMC - PubMed
    1. Weiner DL, Balasubramaniam V, Shah SI, et al. . COVID-19 impact on research, lessons learned from COVID-19 research, implications for pediatric research. Pediatr Res 2020;88:148–50. 10.1038/s41390-020-1006-3 - DOI - PubMed
    1. Marquis-Gravel G, Roe MT, Robertson HR, et al. . Rationale and design of the aspirin Dosing-A Patient-Centric trial assessing benefits and long-term effectiveness (adaptable) trial. JAMA Cardiol 2020;5:598–607. 10.1001/jamacardio.2020.0116 - DOI - PubMed
    1. Orri M, Lipset CH, Jacobs BP, et al. . Web-Based trial to evaluate the efficacy and safety of tolterodine ER 4 Mg in participants with overactive bladder: remote trial. Contemp Clin Trials 2014;38:190–7. 10.1016/j.cct.2014.04.009 - DOI - PubMed

Publication types

Substances

Associated data